Payment overview · 2025
General Payments
$75.02
3 reported records · 3 companies
Healthcare provider profile · identity verified
Ryan Edward Jones, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FORT WORTH, TX · NPI 1033559778
Verified facts
What the public records show
CMS Open Payments records show Ryan Edward Jones, M.D. received $75.02 in general payments during 2025 across 3 reported records.
Inspire Medical Systems, Inc. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.09 | 38.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.46 | 37.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.47 | 23.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $75.02 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.09 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 222 | 68 |
| Gabapentin | Gabapentin | 172 | 44 |
| Lisinopril | Lisinopril | 162 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 149 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 117 | 24 |
| Metformin Hcl | Metformin Hcl | 95 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 24 |
| Furosemide | Furosemide | 92 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 22 |
| Omeprazole | Omeprazole | 74 | 21 |
| Losartan Potassium | Losartan Potassium | 71 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 17 |
| Baclofen | Baclofen | 68 | 20 |
| Trazodone Hcl | Trazodone Hcl | 64 | 20 |
| Carvedilol | Carvedilol | 61 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 11 |
| Tramadol Hcl | Tramadol Hcl | 57 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 16 |
| Ozempic | Semaglutide | 53 | 12 |
| Potassium Chloride | Potassium Chloride | 53 | 18 |
| Eliquis | Apixaban | 51 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Sertraline Hcl | Sertraline Hcl | 48 | 15 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | 11 |
| Famotidine | Famotidine | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 14 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 14 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Meloxicam | Meloxicam | 25 | 11 |
| Simvastatin | Simvastatin | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Celecoxib | Celecoxib | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $75.02 · 3 records | Inspire Medical Systems, Inc. | INSPIRE, TZIELD, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with SANOFI-AVENTIS U.S. LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error